Trial
NCT04119830
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
Merck Sharp & Dohme LLC
Condition
Metastatic Colorectal Adenocarcinoma
Intervention
Pembrolizumab
Why stopped
implementation issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-08